EN DE

Eagle Veterinary Technology Co (044960) Fair Value & Analysis

Healthcare · KR · Market cap 37.4B KRW

EV Eagle Veterinary Technology Co 044960 · KQ
Price3,150 KRW
Fair Value5,669 KRW
Upside+80.0%
Quality62/100
Watch Eagle Veterinary Technology Co for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 5.8% net margin
Low debt · generates free cash flow
1.40% dividend yield
Ranks above peers (9/9)
Narrow moat 31/100
Evidence: High Range 3,843 KRW – 7,299 KRW Share as image

Fair value as of: Jul 20, 2026

From 23 valuation models · updated 21 days ago

Share price +3.1% over the past month.

A solid business, screening 80% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (3,843 KRW). The market is more pessimistic than our downside scenario.
  • Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (3,843 KRW to 7,299 KRW) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

8,587 KRW 2,765 KRW Fair Value 5,669 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.

How to read this chart

60‑month range 2,765 KRW – 8,587 KRW · fair‑value band 3,843 KRW – 7,299 KRW · the 3,150 KRW price screens below the 5,669 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Eagle Veterinary Technology Co (044960) currently trades at 3,150 KRW, while our model-based Fair Value estimate is 5,669 KRW, implying the stock looks roughly 80.0% undervalued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Eagle Veterinary Technology Co generated revenue of 44.0B KRW at a net margin of 5.8%. Revenue grew 11.9% year over year. Net debt stands at 309M KRW. Fundamentals as of Jul 20, 2026

Our scenario range runs from 3,843 KRW (bear case) to 7,299 KRW (bull case); at 3,150 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at 80%, 044960 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 3,602 KRW 4,998 KRW 6,915 KRW 80
Residual Income 3,384 KRW 3,601 KRW 3,981 KRW 76
Rev-Margin DCF 3,275 KRW 4,899 KRW 6,657 KRW 74
All 23 models by family
DCF Models
FCF DCF 3,509 KRW 5,020 KRW 7,190 KRW 38
Owner Earnings 3,378 KRW 4,828 KRW 6,913 KRW 31
5Y Revenue Exit 3,275 KRW 4,866 KRW 6,828 KRW 39
5Y EBITDA Exit 4,073 KRW 6,294 KRW 8,786 KRW 41
5Y P/E Exit 4,277 KRW 6,659 KRW 9,047 KRW 38
10Y Revenue Exit 3,241 KRW 4,683 KRW 6,474 KRW 36
10Y EBITDA Exit 3,832 KRW 5,651 KRW 7,908 KRW 37
10Y P/E Exit 3,960 KRW 5,898 KRW 8,099 KRW 35
Earnings-Based
Graham-Dodd 2,122 KRW 5,157 KRW 6,667 KRW 54
PEG = 1.0 917.59 KRW 1,311 KRW 1,704 KRW 46
EPV 3,150 KRW 3,642 KRW 4,073 KRW 59
Multiples
P/E Multiple 5,150 KRW 6,866 KRW 8,583 KRW 63
P/S Multiple 3,979 KRW 5,306 KRW 6,632 KRW 58
P/B Multiple 3,979 KRW 5,306 KRW 6,632 KRW 55
EV/EBIT 4,590 KRW 6,055 KRW 7,520 KRW 53
EV/EBITDA 4,982 KRW 6,577 KRW 8,172 KRW 54
EV/Revenue 3,332 KRW 4,676 KRW 6,020 KRW 43
Asset-Based
NCAV (Graham) 2,053 KRW 2,751 KRW 4,106 KRW 50
Growth DCF
Growth DCF 3,602 KRW 4,998 KRW 6,915 KRW 80
Rev-Margin DCF 3,275 KRW 4,899 KRW 6,657 KRW 74
Economic Profit
Residual Income 3,384 KRW 3,601 KRW 3,981 KRW 76
ROIC Compounder 3,150 KRW 3,642 KRW 4,073 KRW 72
Growth Earnings
Growth-Adj P/E 3,922 KRW 5,603 KRW 7,284 KRW 68

Widest divergence: Growth Earnings (5,603 KRW) versus Asset-Based (2,751 KRW). Highest evidence: Growth DCF (80).

Notify me when 044960 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 44.0B KRW
Revenue growth (YoY) +11.9%
Net margin 5.8%
Return on equity 696%
Free cash flow 3.9B KRW FY2025
Operating margin 5.9%
More key figures
Dividend yield 1.4%
EPS growth (YoY) -79.3%
Net debt 309M KRW FY2025

Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 62/100

Of which business quality 63 · Market factors (momentum, volatility) 28

Profitability 43
Margins and returns on capital today
Quality Growth 46
Are margins and returns improving?
Cashflow 54
Earnings quality: real cash, not paper profit
Fin. Strength 83
Balance sheet, leverage, solvency risk
Investment 77
Disciplined investing over empire-building
Low Volatility 70
Calm price path (market factor)
Momentum 10
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Eagle Veterinary Technology Co.,Ltd manufactures and sells animal health care products in South Korea. The company offers antibiotics, antibacterials, anthelmintics, antihistamins, and in the form of injectable, feed additives, oral liquids, and soluble powders for swine, poultry, and bovine.

Full company description

Eagle Veterinary Technology Co.,Ltd manufactures and sells animal health care products in South Korea. The company offers antibiotics, antibacterials, anthelmintics, antihistamins, and in the form of injectable, feed additives, oral liquids, and soluble powders for swine, poultry, and bovine. Eagle Veterinary Technology Co.,Ltd also exports its products to New Zealand, Australia, Vietnam, Kenya, Uganda, Rwanda, and internationally. The company was formerly known as Eagle Chemical Co., Ltd and changed its name to Eagle Veterinary Technology Co.,Ltd in June 2000. Eagle Veterinary Technology Co.,Ltd was founded in 1970 and is headquartered in Yesan, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Eagle Veterinary Technology Co reported revenue of 43.3B KRW in FY2025 versus 40.4B KRW in FY2021, a compound +1.7%/yr. Reported net income was 3.9B KRW in FY2025, compounding +2.1%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
43.3B KRW
Latest YoY
+3.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.2%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.4%
Avg. growth/yr (11Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.2%
Revenue +1.7%/yr
FY21 40.4B KRW
FY22 43.5B KRW
FY23 42.8B KRW
FY24 41.7B KRW
FY25 43.3B KRW
Net income +2.1%/yr
FY21 3.6B KRW
FY22 2.6B KRW
FY23 3.0B KRW
FY24 3.7B KRW
FY25 3.9B KRW

Watch 044960: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Eagle Veterinary Technology Co Fair Value". https://www.fairvalue-calculator.com/stock/044960

Peer Group

Pharmaceuticals · 25 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 62 · Top 25%
Fair Value upside +80% · Top 25%
Return on assets 3% · Above median
Net margin (TTM) 6% · Above median
Operating margin (TTM) 6% · Above median
Revenue growth 12% · Above median
Dividend yield (TTM) 1.4% · Above median
Debt / equity 0.04× · Lower than median

Valuation Multiples vs Pharmaceuticals median · lower = cheaper

P/FCF 0.0× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 6
FUTURE 60 · sector 60
PAST 0 · sector 0
HEALTH 98 · sector 96
DIVIDEND 28 · sector 28

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).

Stock Price Fair Value vs Fair Value
GlaxoSmithKline Pharmaceuticals Limited 500660 ₹2,653 ₹1,471 -45%
Caregen Co 214370 62,700 KRW 7,277 KRW -88%
ST Pharm Co 237690 123,600 KRW 50,110 KRW -59%
Oscotec Inc 039200 31,050 KRW 25,062 KRW -19%
DongKook Pharmaceutical Co 086450 18,350 KRW 32,142 KRW +75%
Kolon Life Science Inc 102940 30,100 KRW 37,195 KRW +24%
Huons Global Co 084110 23,800 KRW 58,482 KRW +146%
BINEX Co 053030 6,350 KRW 1,844 KRW -71%
Anterogen.Co.,Ltd., a bio-venture company, 065660 16,810 KRW 4,741 KRW -72%
EURO EURO 1.09 PHP 0.8700 PHP -20%

Compare Eagle Veterinary Technology Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Eagle Veterinary Technology Co (044960) overvalued or undervalued?
As of Jul 20, 2026, our model estimates a fair value of 5,669 KRW versus a price of 3,150 KRW, about +80% (undervalued).
What is the fair value of 044960?
Our model-based fair value for Eagle Veterinary Technology Co is 5,669 KRW (as of Jul 20, 2026), built from audited fundamentals. The current price is 3,150 KRW.
What is the quality score of 044960?
Eagle Veterinary Technology Co has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Eagle Veterinary Technology Co (044960)?
Eagle Veterinary Technology Co reported trailing-twelve-month revenue of about 44.0B KRW (latest available figure, as of Jul 20, 2026).
What is the net profit margin of 044960?
The net profit margin of Eagle Veterinary Technology Co is about 5.8%, meaning it keeps roughly 5.8% of revenue as net income. Based on the latest reported figures.
Does Eagle Veterinary Technology Co pay a dividend?
Eagle Veterinary Technology Co currently shows a dividend yield of about 1.40% relative to its recent price (as of Jul 20, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Eagle Veterinary Technology Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.